Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New mRNA HIV vaccine combo enters first human safety trial

NCT ID NCT06557785

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 22 times

Summary

This early-stage trial tests two experimental mRNA vaccines designed to train the immune system to make powerful antibodies that could block HIV. The study involves 53 healthy adults without HIV to check if the vaccines are safe and trigger the desired immune responses. The goal is to lay the groundwork for a future HIV vaccine.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center (Site ID: 32077)

    Boston, Massachusetts, 02215, United States

  • Columbia P&S (Site ID: 30329)

    New York, New York, 10032, United States

  • New York Blood Center (Site ID: 31801)

    New York, New York, 10065, United States

  • Penn Prevention (Site ID: 30310)

    Philadelphia, Pennsylvania, 19104, United States

  • Seattle Vaccine and Prevention (Site ID: 30331)

    Seattle, Washington, 98104, United States

  • University of Pittsburgh (Site ID: 1001)

    Pittsburgh, Pennsylvania, 15213, United States

  • Vaccine Trial Centre, Mahidol University CRS (Site ID: 32021)

    Bangkok, Ratchathewi, 10400, Thailand

Conditions

Explore the condition pages connected to this study.